Patents by Inventor MARK LAUGHLIN

MARK LAUGHLIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8556397
    Abstract: An ink container usable with an image forming apparatus having a carriage to transport the ink container in a reciprocating motion across a substrate and an ink ejector to eject the ink onto the substrate is included. The ink container includes a chamber configured to supply ink to the ink ejector of the image forming apparatus. The ink container also includes a separation member disposed within the chamber configured to separate unwanted particles from the ink in response to the reciprocating motion of the carriage and gravity, and to direct the ink downstream to the ink ejector.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: October 15, 2013
    Assignee: Hewlett-Packard Development Company, L. P.
    Inventors: Jon Rittgers, Odhran Hendley, Mark Laughlin, Eduardo Macias, Michael Mulloy, Bryan Murphy
  • Publication number: 20120013688
    Abstract: An ink container usable with an image forming apparatus having a carriage to transport the ink container in a reciprocating motion across a substrate and an ink ejector to eject the ink onto the substrate is included. The ink container includes a chamber configured to supply ink to the ink ejector of the image forming apparatus. The ink container also includes a separation member disposed within the chamber configured to separate unwanted particles from the ink in response to the reciprocating motion of the carriage and gravity, and to direct the ink downstream to the ink ejector.
    Type: Application
    Filed: December 15, 2009
    Publication date: January 19, 2012
    Inventors: Jon Rittgers, Odhran Hendley, Mark Laughlin, Eduardo Macias, Michael Mulloy, Bryan Murphy
  • Publication number: 20100261739
    Abstract: A method of treating non-small cell lung cancer (NSCLC), and especially NSCLC that has metastasized to brain is disclosed.
    Type: Application
    Filed: February 16, 2010
    Publication date: October 14, 2010
    Applicant: Myriad Pharmaceuticals, Inc.
    Inventor: Mark Laughlin
  • Publication number: 20100137342
    Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a vascular disrupting agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions that are responsive to disruption of the vascular system, and in particular to its use in treating vascular macular degeneration.
    Type: Application
    Filed: October 6, 2009
    Publication date: June 3, 2010
    Applicant: Myriad Pharmaceuticals, Inc.
    Inventors: Mark Laughlin, Thomas L. Thorne
  • Publication number: 20100129470
    Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a cytotoxic agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating brain cancer.
    Type: Application
    Filed: October 8, 2009
    Publication date: May 27, 2010
    Applicant: Myriad Pharmaceuticals, Incorporated
    Inventor: MARK LAUGHLIN
  • Publication number: 20100093773
    Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a vascular disrupting agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating cancer.
    Type: Application
    Filed: October 6, 2009
    Publication date: April 15, 2010
    Applicant: Myriad Pharmaceuticals, Inc.
    Inventors: MARK LAUGHLIN, Mark B. Anderson, Adam Willardsen, Chris Pleiman
  • Publication number: 20100087457
    Abstract: In general, the invention relates to a pharmaceutical dose having (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride as the active ingredient that upon administration to a subject provides a Cmax of about 1 ng/mL to about 250 ng/mL. The dose may be used in methods of treating cancer through the administration of (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.
    Type: Application
    Filed: October 7, 2009
    Publication date: April 8, 2010
    Applicant: Myriad Pharmaceuticals, Inc
    Inventor: MARK LAUGHLIN
  • Publication number: 20100087458
    Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a cytotoxic agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating melanoma.
    Type: Application
    Filed: October 7, 2009
    Publication date: April 8, 2010
    Applicant: Myriad Pharmaceuticals, Inc.
    Inventor: Mark Laughlin
  • Publication number: 20080033045
    Abstract: The invention relates to the treatment of psychiatric disorders.
    Type: Application
    Filed: July 9, 2007
    Publication date: February 7, 2008
    Applicant: Myriad Genetics, Incorporated
    Inventors: Mark Laughlin, Kenton Zavitz, Suzanne Hendrix
  • Publication number: 20070015832
    Abstract: The invention relates to methods of treating or slowing the onset of overactive bladder or urinary incontinence, or a symptom thereof selected from urinary frequency, urinary urgency, nocturia, or enuresis comprising identifying and administering to a subject in need of treatment a therapeutically effective amount of a compound according to Formulae I-V, as defined herein.
    Type: Application
    Filed: July 14, 2006
    Publication date: January 18, 2007
    Applicant: Myriad Genetics, Incorporated
    Inventor: Mark Laughlin
  • Publication number: 20070004635
    Abstract: A method of treating, preventing or ameliorating one or more symptoms associated with hepatitis C virus (HCV) in a patient in whom either the HCV is of Genotype 1 and/or the patient was previously treated with interferon and the previous interferon therapy was ineffective to treat the one or more symptoms associated with HCV, comprising administering to such a patient an effective amount of at least one compound of formulae I-XXVI of which the following structural formula is exemplary or a pharmaceutically acceptable salt, solvate or ester thereof. Optional combined administration of said at least one compound with an interferon or pegylated interferon and/or ribaviron is also contemplated.
    Type: Application
    Filed: May 31, 2006
    Publication date: January 4, 2007
    Inventors: Janice Albrecht, Mark Laughlin, Bruce Malcolm